Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
SWOG S1702 study of isatuximab for relapsed/refractory AL amyloidosis shows heme response rate 77.1% (57% VGPR or better), median time to PR or better of 1.1 months, renal response 50% (7/14), cardiac response 57% (8/14).”
Title: Isatuximab for Relapsed and/or Refractory AL Amyloidosis: Results of a Prospective Phase 2 Trial (SWOG S1702)
Authors: Terri Parker, Adam Landon Rosenthal, Vaishali Sanchorawala, Heather J Landau, Erica L. Campagnaro, Prashant Kapoor, Natalia Neparidze, Saulius K. Girnius, Patrick Hagen, Emma C Scott, Antje Hoering, Brian G.M. Durie, Robert Z Orlowski
You can read the Full Article in Blood.
You can find more posts featuring Robert Orlowski on OncoDaily.
